WANY
RPRX icon

Wealthspire Advisors (New York)’s Royalty Pharma RPRX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-86
Closed -$3.04K – 2498
2025
Q3 		$3.04K Buy
+86
New +$3.11K ﹤0.01% 2478
2020
Q4 		– Sell
-52,560
Closed -$2.21M – 591
2020
Q3 		$2.21M Hold
52,560
– – 0.13% 76
2020
Q2 		$85K Buy
+52,560
New +$2.6M 0.01% 273

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wealthspire Advisors (New York)'s RPRX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 86 shares — an estimated $3.04K sold.

Wealthspire Advisors (New York) first reported a position in RPRX in Q2 2020 and held it in 3 quarters. The position peaked at $2.21M in Q3 2020. 540 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 86 Royalty Pharma shares in Q4 2025, an estimated $3.04K.
  • Wealthspire Advisors (New York) first reported a position in Royalty Pharma in Q2 2020 and held it in 3 quarters.
  • Wealthspire Advisors (New York)'s Royalty Pharma position peaked at $2.21M in Q3 2020.
  • 540 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.